Published in Gastroenterol Hepatol (N Y) on January 01, 2011
Current management of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) (2014) 1.10
Diagnosis and treatment of hepatocellular carcinoma: An update. World J Hepatol (2015) 1.02
Hepatocellular carcinoma: a review. J Hepatocell Carcinoma (2016) 0.95
Inherent and acquired resistance to paclitaxel in hepatocellular carcinoma: molecular events involved. PLoS One (2013) 0.88
Extracellular vesicle long noncoding RNA as potential biomarkers of liver cancer. Brief Funct Genomics (2015) 0.87
A dual-slot microwave antenna for more spherical ablation zones: ex vivo and in vivo validation. Radiology (2013) 0.85
Urotensin-II-Mediated Reactive Oxygen Species Generation via NADPH Oxidase Pathway Contributes to Hepatic Oval Cell Proliferation. PLoS One (2015) 0.80
Identification of FN1BP1 as a novel cell cycle regulator through modulating G1 checkpoint in human hepatocarcinoma Hep3B cells. PLoS One (2013) 0.80
Circulating biomarkers of hepatocellular carcinoma response after locoregional treatments: New insights. World J Hepatol (2015) 0.79
Hepatocellular carcinoma and other malignancies in autoimmune hepatitis. Dig Dis Sci (2013) 0.79
Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer. Toxins (Basel) (2016) 0.78
Gemcitabine and cisplatin-based combination chemotherapy in advanced hepatocellular carcinoma: An Indian experience. Indian J Med Paediatr Oncol (2012) 0.78
G3BP1 contributes to tumor metastasis via upregulation of Slug expression in hepatocellular carcinoma. Am J Cancer Res (2016) 0.75
Recombinant heat shock protein 70 functional peptide and alpha-fetoprotein epitope peptide vaccine elicits specific anti-tumor immunity. Oncotarget (2016) 0.75
Pulmonary complications of transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Respirol (2016) 0.75
Clinical significance and prognostic value of SOX7 expression in liver and pancreatic carcinoma. Mol Med Rep (2017) 0.75
High correlation between microbubble contrast-enhanced ultrasound, magnetic resonance and histopathology in the evaluation of hepatocellular carcinoma. Einstein (Sao Paulo) (2013) 0.75
Comparison of microwave ablation and hepatic resection for hepatocellular carcinoma: a meta-analysis. Onco Targets Ther (2017) 0.75
Downregulation of serum RAB27B confers improved prognosis and is associated with hepatocellular carcinoma progression through PI3K-AKT-P21 signaling. Oncotarget (2017) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med (1996) 22.46
Chronic hepatitis B. Hepatology (2007) 13.75
Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet (1981) 13.54
Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis (1999) 12.31
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet (2002) 12.16
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology (2003) 11.55
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA (2006) 10.58
Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology (2003) 10.11
Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol (2009) 9.84
Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer (1985) 7.67
Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med (2002) 6.20
Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology (2001) 6.19
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology (2002) 5.71
Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology (1999) 5.70
A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg (2006) 5.65
Diagnosis and management of autoimmune hepatitis. Hepatology (2010) 5.27
Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology (1999) 4.99
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol (2009) 4.82
Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology (2008) 4.73
Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis (2005) 4.51
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol (2001) 4.46
Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology (2004) 4.26
Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology (2008) 4.26
An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg (1999) 4.26
Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology (2003) 4.13
Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut (2001) 4.12
Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology (2010) 3.98
Loco-regional treatment of hepatocellular carcinoma. Hepatology (2010) 3.59
Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology (2009) 3.57
Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology (2008) 3.52
Simplified staging for hepatocellular carcinoma. J Clin Oncol (2002) 3.48
The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl (2002) 3.44
Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology (2000) 3.42
Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology (2000) 3.30
A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology (2005) 3.26
Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology (2001) 3.26
Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology (2002) 3.16
Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol (2006) 3.09
A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant (2009) 3.09
Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology (2002) 2.83
A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst (2005) 2.73
Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials. Aliment Pharmacol Ther (2006) 2.63
Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl (2010) 2.57
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol (2005) 2.56
A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl (2005) 2.56
Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology (1998) 2.52
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol (2008) 2.40
Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol (2009) 2.33
Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology (2009) 2.25
Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl (2008) 2.04
Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl (2002) 2.03
Significance of resection margin in hepatectomy for hepatocellular carcinoma: A critical reappraisal. Ann Surg (2000) 2.01
Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant (2007) 2.00
Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. Ann Surg Oncol (2009) 1.97
Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology (1998) 1.97
Prognostic value of Child-Turcotte criteria in medically treated cirrhosis. Hepatology (1984) 1.95
Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol (2007) 1.95
Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med (1993) 1.89
Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg (2009) 1.85
EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res (2006) 1.85
Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology (1998) 1.83
Liver transplantation for hepatocellular carcinoma. Semin Liver Dis (1999) 1.78
Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP) Am J Gastroenterol (1998) 1.74
Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg (2001) 1.66
Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark (2007) 1.65
Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol (2010) 1.62
Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys (2006) 1.61
Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol (2005) 1.57
Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology (2004) 1.57
A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. Hepatology (1995) 1.57
Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol (2009) 1.51
Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol (2007) 1.49
Eight-year follow-up of the 90,000-person Haimen City cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol Biomarkers Prev (2002) 1.49
Organ Procurement and Transplantation Network--HRSA. Final rule with comment period. Fed Regist (1998) 1.45
Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol (2010) 1.23
Hepatocellular carcinoma: microwave ablation with multiple straight and loop antenna clusters--pilot comparison with pathologic findings. Radiology (2006) 1.20
Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection. Cancer (1996) 1.16
Liver transplant waiting time does not correlate with waiting list mortality: implications for liver allocation policy. Liver Transpl (2000) 1.14
Clinical utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma: special reference to imaging diagnosis. J Hepatol (1999) 1.14
Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology (1997) 1.04
Usefulness of measurement of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma. Am J Gastroenterol (1999) 1.02
Clinical advantage of highly sensitive on-chip immunoassay for fucosylated fraction of alpha-fetoprotein in patients with hepatocellular carcinoma. Dig Dis Sci (2010) 1.00
Therapeutic Ivalon embolization of hepatic tumors. AJR Am J Roentgenol (1982) 1.00
Relative risks of death due to liver disease among Japanese male adults having various statuses for hepatitis B s and e antigen/antibody in serum: a prospective study. Hepatology (1988) 0.96
Phase II study of transarterial embolization in European patients with hepatocellular carcinoma: need for controlled trials. Hepatology (1994) 0.90
Liver transplantation with the Meld system: a prospective study from a single European center. Am J Transplant (2006) 0.89
Local ablation therapy for hepatocellular carcinoma. Semin Liver Dis (1999) 0.88
Surgical treatment of hepatocellular carcinoma in cirrhosis: liver resection or transplantation? Transplant Proc (1993) 0.88
Evaluation of curability and prediction of prognosis after surgical treatment for hepatocellular carcinoma by lens culinaris agglutinin-reactive alpha-fetoprotein. Int J Oncol (1999) 0.85
A multidisciplinary approach to the management of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) (2010) 0.84
Treatment of hepatocellular carcinoma associated with advanced cirrhosis by transcatheter arterial chemoembolization using autologous blood clot: a preliminary report. Hepatology (1992) 0.80
Diagnosis and management of hepatocellular carcinoma: results of a consensus meeting of The Ottawa Hospital Cancer Centre. Curr Oncol (2010) 0.78
The impact of race/ethnicity on the clinical epidemiology of autoimmune hepatitis. J Clin Gastroenterol (2012) 2.20
Development of hepatocellular carcinoma in autoimmune hepatitis patients: a case series. Dig Dis Sci (2010) 1.70
A clinical assessment of Wilson disease in patients with concurrent liver disease. J Clin Gastroenterol (2011) 0.83
Hepatocellular carcinoma: locoregional and targeted therapies. Gastroenterol Clin North Am (2011) 0.77
Coadministration of telaprevir and transcatheter arterial chemoembolization in hepatitis C virus-associated hepatocellular carcinoma. World J Hepatol (2013) 0.75
Hepatic artery pseudoaneurysm: a rare cause of gastrointestinal bleeding in a post liver transplant patient. J Gastrointestin Liver Dis (2012) 0.75